Insider Transactions in Q4 2025 at Becton Dickinson & CO (BDX)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 26
2025
|
Michael Feld EVP, CRO & Pres. Life Sciences |
SELL
Open market or private sale
|
Direct |
74
-0.45%
|
$14,504
$196.08 P/Share
|
|
Dec 17
2025
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
SELL
Open market or private sale
|
Direct |
629
-4.58%
|
$123,284
$196.03 P/Share
|
|
Dec 01
2025
|
Michael Feld EVP, CRO & Pres. Life Sciences |
SELL
Open market or private sale
|
Direct |
75
-0.45%
|
$14,475
$193.36 P/Share
|
|
Dec 01
2025
|
Robert Luther Huffines Director |
BUY
Grant, award, or other acquisition
|
Direct |
180
+50.0%
|
-
|
|
Dec 01
2025
|
Jacqueline Wright Director |
BUY
Grant, award, or other acquisition
|
Direct |
180
+50.0%
|
-
|
|
Nov 26
2025
|
Pavan Kumar Mocherla EVP & President, Greater Asia |
BUY
Grant, award, or other acquisition
|
Direct |
2,916
+20.67%
|
-
|
|
Nov 26
2025
|
David Shan EVP and Chief ISC Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
134
-1.47%
|
-
|
|
Nov 26
2025
|
David Shan EVP and Chief ISC Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,529
+20.19%
|
-
|
|
Nov 26
2025
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,454
-10.32%
|
-
|
|
Nov 26
2025
|
Shana Carol Neal EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,252
+18.92%
|
-
|
|
Nov 26
2025
|
Roland Goette EVP and President, EMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
138
-0.79%
|
-
|
|
Nov 26
2025
|
Roland Goette EVP and President, EMEA |
BUY
Grant, award, or other acquisition
|
Direct |
3,143
+8.61%
|
-
|
|
Nov 26
2025
|
Michael Feld EVP, CRO & Pres. Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
419
-2.45%
|
-
|
|
Nov 26
2025
|
Michael Feld EVP, CRO & Pres. Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
8,829
+34.08%
|
-
|
|
Nov 26
2025
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
SELL
Payment of exercise price or tax liability
|
Direct |
1,769
-11.41%
|
-
|
|
Nov 26
2025
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
BUY
Grant, award, or other acquisition
|
Direct |
10,616
+27.11%
|
-
|
|
Nov 26
2025
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,245
-15.59%
|
-
|
|
Nov 26
2025
|
Christopher Del Orefice EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,006
+18.07%
|
-
|
|
Nov 26
2025
|
Bilal Muhsin EVP & President Connected Care |
BUY
Grant, award, or other acquisition
|
Direct |
9,530
+30.47%
|
-
|
|
Nov 26
2025
|
Richard Byrd EVP & President Interventional |
SELL
Payment of exercise price or tax liability
|
Direct |
1,719
-11.04%
|
-
|
|
Nov 26
2025
|
Richard Byrd EVP & President Interventional |
BUY
Grant, award, or other acquisition
|
Direct |
8,832
+23.06%
|
-
|
|
Nov 26
2025
|
Thomas E Polen Jr Chairman, CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
17,421
-14.18%
|
-
|
|
Nov 26
2025
|
Thomas E Polen Jr Chairman, CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
22,521
+15.49%
|
-
|
|
Nov 26
2025
|
Pamela L. Spikner SVPController & Chief Acct Off |
BUY
Grant, award, or other acquisition
|
Direct |
1,234
+39.17%
|
-
|
|
Nov 07
2025
|
Bertram L Scott Director |
SELL
Open market or private sale
|
Direct |
217
-0.6%
|
$38,192
$176.58 P/Share
|
|
Oct 27
2025
|
Michael Feld EVP, CRO & Pres. Life Sciences |
SELL
Open market or private sale
|
Direct |
57
-0.69%
|
$10,602
$186.01 P/Share
|